Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy
Conditions
Interventions
Nusinersen
Sham procedure
Locations
24
United States
UCLA Clinical and Translational Research Center
Los Angeles, California, United States
Lucile Packard Children's Hospital at Stanford
Palo Alto, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Nemours Children's Hospital
Orlando, Florida, United States
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Start Date
November 24, 2014
Primary Completion Date
February 20, 2017
Completion Date
February 20, 2017
Last Updated
February 17, 2021
NCT06321965
NCT07332702
NCT07265232
NCT05824169
NCT06756633
NCT05638750
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions